A study to evaluate CM24 in combination with nivolumab in adults with solid tumours
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2540836
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Part A• To assess the safety, tolerability and the maximum tolerated dose (MTD) of CM24 in combination with 480mg nivolumab in adults with selected recurrent or metastatic solid tumors.• Determine the recommended Phase 2 dose level (RP2D) of CM24 in combination with nivolumab
Part BTo assess the efficacy of the recommended phase 2 dose (RP2D) of CM24 in combination with nivolumab in adults with immune-checkpoint refractory recurrent or metastatic NSCLC based on Objective Response Rate (ORR).
Part CTo assess the efficacy of CM24 in combination with nivolumab and nabpaclitaxel in adults with metastatic pancreatic cancer based on Objective Response Rate.
Primary endpoints: Part ASafety and tolerability
Parts B and CObjective response rate (ORR) based on RECIST Version 1.1
创建时间：
2021-11-15
